曲贝替定（ET-743，Yondelis）在转移性子宫平滑肌肉瘤中的活性。
Activity of trabectedin (ET-743, Yondelis) in metastatic uterine leiomyosarcoma.
作者信息
Tewari Devansu, Saffari Bahman, Cowan Carol, Wallick Anita C, Koontz M Zach, Monk Bradley J
机构信息
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA 92868, USA.
出版信息
Gynecol Oncol. 2006 Sep;102(3):421-4. doi: 10.1016/j.ygyno.2006.04.025. Epub 2006 Jun 23.
BACKGROUND
The ongoing search for more effective agents in the treatment of uterine leiomyosarcomas is warranted because of the poor prognosis related to these tumors.
CASE
A case of advanced, recurrent and refractory uterine leiomyosarcoma is presented that responded to trabectedin (ET-743) 1.2 mg/m2 intravenously over 24 h every 3 weeks after failing four prior regimens. A durable objective response lasting at least 8 months was documented.
CONCLUSION
Trabectedin (ET-743) has activity in uterine leiomyosarcoma and warrants further investigation.
背景
由于子宫平滑肌肉瘤预后较差，因此有必要继续寻找更有效的治疗药物。
病例
报告了一例晚期、复发性和难治性子宫平滑肌肉瘤病例，该病例在先前四种治疗方案失败后，每3周接受一次曲贝替定（ET-743）1.2 mg/m²静脉滴注，持续24小时，出现了持久的客观缓解，持续至少8个月。
结论
曲贝替定（ET-743）对子宫平滑肌肉瘤有活性，值得进一步研究。
Zotero 插件